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ABSTRACT
Evaluation of Antiviral Compounds Against
Avian Influenza
by
Evan W. Call, Master of Science
Utah State University, 1991
Major Professor: Dr. Robert W. Sidwell
Department: Animal , Dairy and Veterinary Science
Tests in vitro for antiviral activity against avian influenza viruses,
Murkey/Sanpete/85 (H6N8) and Murkey/Sanpete/86 (H1 ON9) , isolated in
Sanpete County, Utah, utilized known antiviral agents, amantadine•HCI
(adamantanamine hydrochloride) and ribavirin (1-B-D ribofuranosyl-1 ,2,4triazole-3-carboxamide) . The testing involved evaluation of seven drug
concentrations. Maximum tolerated dose , minimum inhibitory concentration
and therapeutic indexes were determined for each drug used. Both drugs
demonstrated reasonable antiviral activity. Then they were tested against the
H1 ON9 strain in 10-day-old Broad White turkey poults. Large- and smallparticle aerosol delivery systems were the delivery methods utilized . Various
parameters, including water and feed consumption, health score (based on
visible signs), recoverable lung virus , lung, hemagglu1ination titer, and visual
lung scoring were considered for the quantification of viral infection and , thus,
antiviral activity in birds . Recovery of viable virus from infected turkey poults
proved sporadic. Visible signs were varied and mild, limiting the usefulness
of health scores. The onset of illness was reflected in the decline in water
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consumption . Moderate antiviral activity was demonstrated with the use of
ribavirin small-particle aerosol , but ribavirin fog was not effective.
Amantadine produced slight antiviral activity when used with both delivery
systems . The potential efficacy of both drugs and application methods
indicate further study of these control systems is warranted .
(72 pages)

INTRODUCTION
The poultry industry is a major portion of the agricultural economy in the
United States and has a large impact upon all of us, especially at the
breakfast and dinner table. Information gathered in 1980 indicates that
chicken is the second most-ordered restaurant meal (Lasley 1984). The
yearly consumption of eggs is 265 per capita. Broiler consumption per person
is 48.6 pounds, and the average person consumes 10.7 pounds of turkey per
year (Lasley 1984). When these levels of consumption are compared , using
the 1967 dollar standard , today 's prices are less than one-half those of 25
years ago (Lasley 1984) .
Avian influenza (AI) has become a major concern to the poultry industry
over the last few years. Due to the trend toward farms with large numbers of
closely confined birds (intensification), control of readily transmissible
diseases such as AI is a critical concern .
The impact of avian influenza on the poultry industry can be
devastating . In the October, 1983, through February, 1984, outbreak in
Virginia alone, losses and depopulation totaled 65 flocks with 1,241 ,746 birds
at a cost of $9 ,446,549 (Van Buskirk 1984) . Estimates of total losses
experienced by the poultry industry in the affected states include 17 million
birds at a cost of approximately $61 million (Webster et al. 1985) .
The current policy of the United States Department of Agriculture
(USDA) in the control of pathogenic AI is the depopulation of flocks infected
with the disease. There is some evidence, however, that depopulation did not
stop the spread of the virus in the Virgin ia outbreak (Van Buskirk 1984) . This
also seems to be the case in the 1985 outbreak in Sanpete Valley, Utah,
where affected and neighboring flocks were processed to depopulate the
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immediate area of the outbreak . Despite these efforts, the disease continued
to spread to other flocks throughout the valley (Ahmed and Jensen 1987). This
justifies the necessity of examining other control alternatives.
Due to the lack of efficacy of the current control measures in practice, we
examined the in vitro and in vivo efficacy of treating avian influenza infections
with amantadine and ribavirin, two drugs known to be inhibitory to the
influenza virus (Dolin et al. 1982; Khare et al. 1973; Oxford 1975a; Oxford
1975b; Sidwell 1980)
Initial experiments were conducted t'? demonstrate the activity of these
compounds against recently isolated influenza viruses, in cell culture utilizing
primary chick embryo fibroblast (CEF) cells; studies then were performed to
examine the in vivo treatment of young (1 0-12 day old) turkey poults infected
with the virus. Because of the ease with which large numbers of birds can be
treated via aerosol, and the current ready availability of large-particle aerosol
systems on many farms , we treated infected birds in separate experiments with
either amantadine or ribavirin , utilizing fogs generated by a commercially
available fogger.
It already has been demonstrated that ribavirin and amantadine are
particularly effic13cious when administered via small-particle aerosol (mean
particle diameter <5 f.!m) (Knight et al. 1980) . Therefore it was of interest to
treat young infected turkey poults with small-particle aerosols of amantadine
and ribavirin. We used a collison-type nebulizer built by the U.S. Army and
powered by compressed air.
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REVIEW OF LITERATURE
Characteristics of Avian Influenza
AI was first described in 1887 in Italy (Stubbs 1965) by Perroncito as "a
serious disease of chickens ." It was not until 1955, however, that the
responsible pathogenic agent was found to be the type A influenza virus
(Bankowski and Samadieh 1980).
Recent AI outbreaks have been unique in several ways. The 1983 1984 Virginia epizootic is the first major outbreak in chickens since 1929
(since 1960 the disease has been primarily a problem in turkeys): it produced
a fowl plague-like disease , with high mortality that was reproducible in the
laboratory (Beard 1984) . Dr. C. W. Beard (1 984) stated that:
Prior to these isolations it was difficult if not impossible to
take influenza virus from a disease outbreak in the field ,
take it to the laboratory and produce disease, especially
high mortality where 23 of 25 or 24 of 26 SPF hens would
die of the laboratory infections .
AI recently has become a disease of importance also in the state of
Utah. In Sanpete Valley of central Utah late in 1986 , 70-80% of the turkey
flocks "had or were experiencing AI " (Ahmed and Jensen 1987). Mortality
rates were as high as 20-30% in 4-7-week-old poults, where Escherichia £Q!i
compl icated the infection .
Part of the difficulty inherent with diagnosis of AI is the broad spectrum
of signs or lesions that are often seen with outbreaks of infections caused by
th is virus. Signs of the infection may be indisti nguishable from Newcastle
disease (U . S. Department of Agricultu re 1984) , and, in fact, in 1964 an
outbreak of what was believed to be Newcastle disease (which also is a
myxovirus or hemagglutinating virus) occurred in turkeys in Modesto,
California. After careful study, however, the virus isolate was found to be an

4

influenza virus (Bankowski and Samadieh 1980) . Signs of the disease were
so varied that
some strains of the virus may cause high mortalities in birds
of any age while others may be of a form so mild that
infection may go undetected (Banko.wski and Samadieh
1980).
Even upon examination at necropsy, the disease signs are not
consistent, nor particularly pathognomonic (Eckroade 1984) . Possible signs
can include depression and droopiness, ruffled feathers , loss of appetite,
sudden drop in egg production , loss of coordination in walking and standing,
cyanosis of comb and wattle or snood, diarrhea, blood tinged discharge at the
nares, circling and paralysis. Upon necropsy, hemorrhages on the mucosa or
lining of the ventriculus, proventriculus , and cardiac muscle may be seen , as
well as necrotic lesions in the liver. spleen and kidneys; enlarged spleen ; and
pneumonic lungs . The development of AI is within 3 to 7 days of exposure,
and death normally follows the onset by 2 to 4 days (U. S. Department of
Agriculture 1984).
Cultivation of Avian Influenza Virus
Influenza virus is readily grown in hens' eggs and, with more difficulty,
in cell culture (Dowdle and Schild 1975); however, eggs still are the
cultivation system of choice for particular applications such as preparation of
large virus pools and vaccine production (Murphy and Webster 1985) .
Many influenza viruses can be readily propagated in cell culture either
in primary CEF cells alone or in one of many other cell lines with addition of
tryps in (Appleyard and Maber 197 4; Beare and Keast 197 4; Klenk et al. 1975) .
These other cell lines would include monkey kidney, calf kidney, primary
bovine kidney, hamster kidney, chicken kidney and human embryonic lung
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cells (Beare and Keast 197 4; Gaush and Smith 1968; Murphy and Webster
1985) .
It is thought that the ability of influenza virus to infect a cell is dependent
on the fusion peptide found in the hemagglutinin (HA) molecule. This peptide,
however, is not ·in a readily accessible antigenic site and a pH-induced
conformational change is required in order for this fusion portion of the HA to
become functional. This conformational change enables the HA molecule to
bind to lipid vesicles and to hemolyze erythrocytes (Murphy and Webster
1985) .
The exposure of F peptide of the HA also may be accomplished by
trypsinization of HA molecule wh ich has been shown to enhance viral
infectivity. Tobita et al. {1975) found that 11 different influenza A viruses
demonstrated increased plaquing efficiency with well-formed and enlarged
plaque size due to addition of the proteolytic enzyme trypsin . This effect was
seen at 5 flg/ml and demonstrated a dose response curve through 20 flg/ml ,
beyond which point no further enhancement was seen.
The treatment of influenza virus with a concentration of 10 flg/ml of
trypsin caused the formation of plaques in CEF cells at or near the same level
of infectivity as shown in 10-day chicken embryos for 6 strains of influenza A
viruses tested (Appleyard and Maber 1974; Beare and Keast 1974) . The
titration of egg-grown virus in MOCK (Madine Darby Canine Kidney) cells
revealed enhancement of plaqueforming infectivity from one-fold for influenza
CK/Germany/34 virus to 1500-fold for influenza virus strain pt/N.I./73 with
trypsin treatment (Alexander, Collins and Parkinson 1981).
The use of trypsin in overlay medium has extended the range of
susceptibility of MOCK cells to include viruses that otherwise cannot be
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assayed in this system , such as influenza AO/PR8, A1 /CAM and Nswine
{Tobita et al. 1975) .
Tobita and Kilbourne (1974) found in cell culture under fluid
maintenance medium without trypsin , using low multiplicity of infection, there
was no evidence of virus growth , indicating an abortive infection . The
inclusion of 2 flg of trypsin per ml in the fluid maintenance medium of primary
CEF cells infected with influenza B/Lee/40 yielded 1Q7 .D 50% egg infective
dose {EIDso) . whereas without trypsin the titer was 1Q4 .3 EIDso. Similar results
also were demonstrated with influenza B/Mass/1/71.
Each virus strain varies from others in their plaquing response to the
trypsinization. This variation is seen in virus titer and in plaque morphology
(Appleyard and Maber 1974; Beare and Keast 1974) .
The difference in response to effects of trypsin among the various
strains of influenza A has also been seen with the AN.JSN strain and with fowl
plague virus , both of which produced good plaques with, and without,
trypsinization. The NSing/1/57 required the presence of trypsin to even show
development of plaques (Appleyard and Maber 1974).
Epidemiology or Transmission
of Avian Influenza Virus
Avian influenza appears to be more readily transmissible than
Newcastle disease. It is very difficult to control spread of the virus. Ninetyseven percent of the 1983-1984 outbreaks that occurred among chickens in
Maryland, Pennsylvania, Virginia and New Jersey took place after it was
publicized that a highly pathogenic AI virus had emerged. It was after
November 9, 1Q83, when the extraordinary emergency was declared and
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quarantine and eradication programs were initiated, that 77% of all outbreaks
in the above states developed (Craig 1984).
In natural infection and chemotherapy studies reported by Lang,
Narayan and Rouse {1970), uninfected turkeys were housed in the same pen
as birds experimentally infected with a highly pathogenic strain of AI
(NTurkey/Ontario/66). Of the original uninfected birds exposed, all not treated
with the antiviral agent amantadine died of avian influenza A contracted by
simple cohabitation with infected birds (Lang , Narayan and Rouse 1970).
Westbury, Turner and Amon {1 981) also showed evidence that the
birds must come in contact with each other in order for the virus to be
effectively transmitted . They did this by placing infected and uninfected birds
in contact on the floor of an isolator house and by also suspending uninfected
birds in cages, one bird's height above the floor containing infected birds.
Under these circumstances, none of the caged birds became infected
(Westbury, Turner and Amon 1981 ). This failure to transmit infection to birds
not in direct contact may have been due to an AI strain variation or because
the birds were housed in a tiled room which was washed out daily. This
practice would eliminate virtually all the dust which, in an on-farm situation,
could serve as a vector in the transmission of the virus.
The 1983-84 outbreak seemed to contradict the idea that birds must
come in direct contact for transmission to occur. This recent outbreak behaved
differently from previous outbreaks in that this outbreak was very difficult to
contain, whereas previous outbreaks tended to be self-limiting due to their
lower transmissibility (Beard 1984) . This was evidenced by the fact that more
than three-quarters of all cases of flock infection occurred after institution of
quarantine and other control measures, such as the restriction of sale of
contaminated birds and depopulation (Craig 1984; Webster et al. 1985) . This
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suggests the potential importance of feral and wild avian species in the
transmission of this virus. Another possibility is human workers (catching
crews and other service crews) functioning as a vector, as was suggested by
the work of Campbell , Webster and Breese (1970) and Webster, Geraci and
Petursson (1981).
Avian lnfluenza .Virus Morphology
The influenza virus itself is approximately 80-120 nm in diameter and is
covered with antigenic projections, or spikes, on the surface. There are 2
different types of surface antigens, the first being the HA antigen, which is
approximately 6 times more numerous than the second antigen,
neuraminidase (Joklik 1985) . The virus is an enveloped, RNA-containing virus
whose genome is divided into 8 segments. The information in Table 1 has
been reproduced from Joklik (1985) and describes each gene and the protein
it encodes.
Of particular interest are genes 4 and 6 {Table 1); gene 4 codes for the
two-part HA protein spike that is responsible for attachment at infection. The
fusion protein is a subprotein of the HA spike. The protein coded by gene 6 is
the neuraminidase protein , also a surface antigen that is used in identification
of influenza viruses.
There are 3 types of influenza: types A, B. and C. Type A is the only one
known to have varying HA and neuraminidase. There are 13 HA antigens and

e neuraminidase antigens currently recognized

(Joklik 1985).
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Table 1.--lnfluenza Virus Genes , the Proteins Encoded and the
Protein Function
Gene

Protein

Protein Function

1

P1
P2

Initiation of transcription

2
3
4

P3
HA1

5

HA2
NP

6
7

NA
M1

8

M2
NS1
NS2

Cap-binding protein
Elongation of transcription
Large portion of HA spike
Smaller portion of HA spike
Nucleocapsid structural protein
Neuraminidase
Matrix protein
Nonstructural, unknown function
Nonstructural , unknown function
Nonstructural , unknown function

from Joklik {1985)
Chemotherapy of Avian Influenza
The number of AI outbreaks taking place during the most stringent
eradication and control efforts makes it quite evident that these methods alone
are not enough. Thus we felt it important to investigate chemotherapy as an
alternative .
Chemotherapy of viral diseases is much more complicated than
treatment of bacterial infection. The obligate intracellular parasitic nature of
viral infections is the major complicating factor, in that the invading virus
utilizes the metabolic, protein and nucleic-acid duplicating mechanisms of the
cell (Joklik 1988). This intimate intracellular relationship between virus and
host cell makes extremely difficult the task of hitting a specific antiviral target
while avoiding adversely affecting the host cell (Robins 1986).
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Current antiviral chemotherapy efforts are directed at one or more
stages of virus infection and replication. One likely target point in this cycle is
the virus attachment to , and penetration of, the cell wall. Drugs designed to
block or occupy the virus-binding sites on the cy1oplasmic membrane would
accomplish this (Oxford 1975b) .
Another target in this cycle would be prevention of the uncoating or
release of the influenza RNA into the cy1oplasm of the cell. This mode of action
has been shown to be how amantadine and rimantadine exert their
prophylactic activity (Bukrinskaya , Vorkunova and Narmanbetova 1980) .
The next logical step would be to inhibit one or more virus-induced or
virus-enhanced metabolic activity or biochemical pathway within the cell. The
nucleosides or nucleoside analogs , trifluridine, vidarabine , acyclovir,
bromovinyl deoxyuridine , deazaadenosine and ribavirin, all are drugs whose
efficacy falls into this category (Sim and McCullagh 1985). Of these inhibitors,
only ribavirin is effective against influenza.
Other important targets for antiviral chemotherapy research include
viral protein maturation , viral capsid assembly, genome packaging, and, for
enveloped viruses like AI , budding (Sim and McCullagh 1985) .
There are a number of agents that have been shown to have antiviral
activity (Sidwell 1986). See Table 2 for a summary of some important clinically
active antiviral drugs. Of particular interest are the first 3 compounds, all of
which have been shown to be active against influenza A viruses.
A major difficulty that can arise in antiviral chemotherapy research is the
occurrence of drug -resistant virus mutants, such as has been shown to occur
with amantadine and its derivatives (Beard, Brugh and Webster 1987; Heider
et al. 1981 ; Webster et al. 1985) . The occurrence of drug-resistant mutants
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Table 2.--Representative Clinically Active Antiviral Drugs
Drug
Amantad ine•HCI

Chemical Name
Viral Disease Inhibited
1-Adamantanamine•HCI Influenza A

Ribavirin

1-B-D-ribofuranosyl1,2,4-triazole-3carboxam ide

Hepatitis, influenza
A and 8 , respiratory
syncytial disease, measles

Rimantadine•HCI

Methyl-1 -adamantanam ine•HCI

Influenza A

Acyclovir

9(2-Hydroxyethoxymethyl)guanine

Herpes eye,
cutaneous and
genital infections

Cytarabine

1-B-D-Arabinofuranosylcytosine

Herpes eye,
cutaneous infections

ldoxuridine

5-lodo-2' -deoxyuridine

Herpes eye,cutaneous
and encephalitis infections

Methisazone

1-Methylisatin-3thiosemicarbazone

Smallpox, severe
vaccinial infections

Trifluorothymidine 5-Trifluoromethyl-2'deoxyuridine

Herpes eye
infections

Vidarabine

9-B-D-arabinofuranosyladenine

Herpes eye, encephalitis
infection

Zidovudine

3'-Azido -3'-deoxythym idine

Acquired immune deficiency
syndrome

Ganciclovir

9-(1 ,3-dihydroxy-2 propoxymethyl)guanine

Cytomegalovirus
infections
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raises a special interest in the antiviral agent ribavirin . Aibavirin has a broad
spectrum antiviral activity which includes a strong efficacy against influenza
viruses (Sidwell 1980) . Of more particular interest in this case, however, is the
fact that no drug-resistant mutants have ever been found with ribavirin (Robins
1986) .
Amantadine (1-adamantanamine hydrochloride). Amantadine is a cyclic
primary amine (Figure 1) that has been shown to be effective against most
influenza A virus infections in many animal species as well as humans
(Hoffmann 1973). It was approved by the U.S. Food and Drug Administration
for use in treatment of Asian influenza (H2N2) in humans in 1966 and in 1976
for use against all influenza A infections (Sim and McCullagh 1985) .

Fig. 1. Structure of amantadine.
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At least 2 mechanisms of action of amantadine are known, which are
dependent on drug concentration. At high concentrations (0.5 mM),
amantadine increases the pH in the endosome containing the virus particle,
stopping fusion of the virus and endosomal membranes due to the inhibition of
the pH dependent HA configuration change, thus preventing the release of the
nucleocapsid into the cytoplasm (Burkinskaya, Vorkunova and Narmanbetova
1980) .

The low concentration inhibition of influenza A viruses by amantadine
occurs early for human viruses and late for _2 different avian strains. This early
vs . late inhibition is dependent on the HA present and maps to the M2 gene
(gene coding for a matrix protein) . This suggests that amantadine may
interfere with a HA-matrix protein interaction (Field and Owen 1988) .
The first to demonstrate the susceptibility of AI in vivo to a
chemotherapeutic agent was Lang, Narayan and Rouse (1970), who was able
to prevent infection and subsequent death of turkeys with oral administration
of amantadine. In their studies , 5 mg amantadine per kg body weight showed
good prophylactic activity. Webster et al. (1985), working with chickens, found
that levels higher than this up to 0.5% amantadine in the drinking water, were
not well accepted. The birds treated at this level suffered reduced weight gain
and in both experiments were susceptible to AI infection at the termination of
treatment. However, at the 0.01% level it was found both amantadine and
rimantadine were well tolerated. with no decrease in weight gain. Both drugs
were effective at this level in preventing clinical signs, as well as infection , as
demonstrated by the fact that only 1 of 10 rjmantadine-treated birds sereconverted. At treatment concentrations of 0 .002% all birds became infected , 1
of 10 died and all others showed signs of infection and recovered with levels of
HA inhibition (HI) antibody with titers >640 .
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It is important to note that the same researchers found that an
amantadine-resistant virus developed during simulated flock treatment and
natural transm ission caused mortality among treated birds (Webster et al.
1985) . This was confirmed by Beard , Brugh and Webster (1987), who showed
that 67% of 10-day-old embryos infected with the resistant virus in the
presence of 400 mg amantadine/egg died .
Karunakaran (1984} studied the effect of treating AI infected turkeys with
amantadine administered by oral gavage, drinking water, or as an aerosol. In
the 5-week-old turkey poults treated with 20 mg/kg/day amantadine once daily
for 6 days beginning 3 days pre-virus exposure, no recoverable virus was
shed . Karunakaran (1984) also reported rimantadine to have moderate postinfection treatment efficiency whereas amantadine did not.
In birds receiving amantadine via aerosol twice a day for 3 days, lung
tissue from 13% of the treated birds yielded recoverable virus, while 33% of
untreated birds produced recoverable virus' which had titers of approximately
1o6 virus particles per gram of tissue (Karunakaran 1984) .
Another parameter of interest in the study of influenza infections is the
reduction of water consumption . Using mice, McGahan and Hoffmann (1968)
showed the reduction of water consumption in infected animals. The degree
of water consumption reduction was correlated with amount of virus given in
the inoculum and coincided with the severity of the disease (McGahan and
Hoffmann 1968) . With decrease in water consumption as the gauge of the
onset of illness, McGahan and Hoffmann (1968) began amantadine
treatments , via oral gavage and drinking water, 12 hours following the onset
of reduction of water intake. Treated animals demonstrated significant
reduction in disease severity, increase in the percent of animals remaining
healthy, and lengthening of mean survival time. It is assumed, then , that the
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water intake, or the absence thereof, could be used as a measure of
prophylactic or efficacious treatment activity.
Because of the moderately positive effect of aerosol treatment we felt it
important to study efficiency of aerosol treatment of amantadine and ribavirin ,
and to compare the relative effectiveness of large- (fog) and small-particle
aerosols.
Ribavirin (1 -B-D-ribofuranosyl-1 2 4-triazole-3-carboxamidel. Ribavirin
is a synthetic nucleoside that resembles guanosine (Figure 2) . It has a truly
broad spectrum of activity including inhibition of both RNA and DNA viruses
(Oxford 1975a, Sidwell 1980, Sidwell et al. 1972).

0

OH

OH

Fig. 2. Structure of ribavirin .
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The precise mechanism of action remains partially unclear because no
drug resistant mutant viruses have been found to help elucidate the
mechanism of action. It is believed that this is due to ribavirin 's having many
sites of action (Robins 1986) .
The mechanism of action of ribavirin 3nd its metabolites is known to be
multi-faceted. Initially, ribavirin monophosphate was shown to be a potent
inhibitor of inosine monophosphate (IMP) dehydrogenase, in both cell-free
(Streeter et al. 1972; Streeter et al. 1973) and viable-cell systems (Smith et al.
1974) , wh ich subsequently inhibited viral nucleic acid synthesis by limiting
production of guanine nucleotides available for that synthesis (Streeter et al.
1977) . Other researchers (Barnett, Shipman Jr. and Drach 1980; Drach,
Thomas and Shipman Jr. 1978; Drach et al. 1981) using [32P] uptake rather
than the [3H] used by Streeter et al. (1977) showed only slight effect on DNA
synthesis, and marked inhibition of phosphorylation of [3H] thymidine, thus
suggesting the actual inhibition of DNA is less than had been assumed.
Sidwell, Revankar and Robins (1985) suggest that the mechanism of
action of ribavirin must not be dependant on the effect on RNA and DNA
synthesis because of the number of viruses against which ribavirin exerts little
or no effect (poliovirus, coxsackie B virus and pseudorabies virus as well as
adenovirus and rhino to varying degrees).
Eriksson et al. (1977) reported that in cell-free systems, between 82
and 90 percent inhibition of influenza virus RNA polymerase by ribavirintriphosphate at the 500

~M

concentration. The triphosphate form of ribavirin

has been reported by Miller et al. (1977) to be found in cells at levels similar to
those of ribavirin-monophosphate.

However, ribavirin and ribavirin-

monophosphate do not show inhibitory activity against influenza virus RNA
polymerase (Eriksson et al. 1977) . It is important to note that stimulation of

influenza virus cANA (Piotch and Krug 1977) can be abolished by ribavirintriphosphate (Eriksson et al. 1977).
The efficiency of translation of mANA grown in the presence of ribavirin
is greatly reduced (Canonico et al. 1980) . Smith et al. (1980) and Goswami et
al. (1979) found that ribavirin exhibited a potent effect on the 5' terminal
guanylation of in vitro synthesized uncapped mANA of vaccinia virus, and
ribavirin may be incorporated into the cap (Smith et al. 1980) . This is further
supported by the fact that ribavirin is poorly active against poliovirus which
does not have the normal 5' cap. These effects on viral mANA may explain, in
large part, ribavirin 's antiviral activity.
Treatment of viral infections with ribavirin aerosols has been effective
against several viral infections (Taber et al. 1983). Currently ribavirin is U. S.
Food and Drug Administration approved for aerosol treatment of respiratory
syncytial vi rus infections in infants.
Treatment of influenza A infections in mice with aerosols of ribavirin has
demonstrated therapeutic activity (Stephen et al. 1976). Stephen and
associates showed ribavirin to be effective when administered as late as 3
days post-infection; however, percent survivors increased from 53% to 93%
when periodic daily treatments began 6 hours post-virus exposure. Extensive
work using ribavirin has been done with influenza A infections in mice (Durr,
Lindh and Forbes 1975; Khare et al. 1973; Stephen et al. 1976) and ferrets
(Schofield et al. 1975) with various treatment routes, but work with ribavirin in
turkey poults has not been reported. Karunakaran (1984) does report some
preliminary work using ribavirin to treat influenza virus infections in chickens.
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MATERIALS AND METHODS

Influenza A/Turkey/Massachusetts/55 (H6N12) {A/Turkey/Mass) was
obtained from the American Type Culture Collection , Rockville, Md.
Influenza A/Turkey/Sanpete/85 (H6N8) and A/Turkey/Sanpete/86
(H1 ON9), were collected and provided by Dr. Marcus Jensen of Brigham
Young University, Provo, Utah .
The A/Turkey/Mass virus was inoculated into the allantoic cavity of 10day-old embryonated hen's eggs and fluids were collected on the day of death
of the embryo. Eggs were refrigerated prior to collection of fluids to reduce the
amount of bleeding during collection.
Fluids collected on the various days of embryo death were pooled and
frozen at -80°C. Aliquots then were thawed and titered via egg inoculation
and by HA.
Virus pools were titered on the days they were collected, with the pool
having the highest titer chosen for developing a larger virus pool. Eggs were
infected as befo.re and on day 3, when 8 of 10 eggs exhibited hemorrhage
and decreased mobility, fluids were collected, centrifuged at 1800 rpm for 3
minutes, aliquoted and frozen at -8ooc. This pool was quantified by HA and
had a mean end point of 1:352. The EIDso was 1Q2.5Jml as determined by the
Reed and Muench (1938) method . The cell culture 50% infectious dose
(CCIDso) of the pool, as assayed in MOCK cells , was 1Q4.4 mi.
Both viruses isolated in Sanpete County were propagated in eggs .
The H 1ON9 virus caused death earlier than the H6N8 virus. However, this
pool was found to be contaminated with two different Staphylococcus and an
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Aeromonas bacterial species . Antibiotic sensitivity tests showed that there
was no single treatment that could eliminate all of the contaminating species.
To verify the source of contamination, a second pool was grown in
eggs using the same H1 ON9 virus pool as inoculum. The fluids from the eggs
in this pool were again plated on LB (Lowenstein Broth) agar (1 0 gm Bacto
tryptone, 5 gm Bacto yeast extract, 5 gm sodium chloride, 13 gm agar/litter, pH
adjusted to 7.5 with NaOH) and the same 3 bacterial colony morphologies
were seen. A flask of primary chick embryo fibroblasts (CEF) cells were also
infected with this seed stock; within 3 days the cells were dead and a grainy
background of motile contam ination was visible.
In an effort to make this pool usable because of its applicability to Utah
agriculture, and its relatively more virulent nature, the virus pool was
centrifuged at 2100 rpm for 5 minutes in an effort to eliminate cellular debris
and most of the bacterial contamination . The pool then was treated with 1
mg/ml of lysozyme and 20 mg of ethylenediaminetetraacetic acid (EDTA)/ml.
A 0.5 ml aliquot of the treated pool then was plated on each of 2 LB agar
plates undilute. After this treatment there was only 1 bacterial colony found on
1 of the plates. The other plate was free of bacterial contamination. The
contaminates were determined to be normal flora of the turkey respiratory
tract; since the route of inoculation of birds was the respiratory tract, it was
decided that this pool would be usable for antiviral drug tests in birds. After
treatment, this virus pool 's EIDso end point was 104 and the CCJD 50 was
1os.3. It should be noted that neither this nor the other viruses used in this
work caused experimentally-induced death in turkeys.
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One-day-old Orrlop, Broad White turkey poults were obtained from the
Moroni Feed Co. Hatchery (Moroni , Utah). These birds were culls or seconds
provided for this research at no cost. Birds were culled as seconds when
visual examination revealed anomalies considered to indicate reduced vigor
in the on-farm environment. Examples of culling criteria could include size,
swollen umbilicus or beak malocclusion. In each case, birds were examined
and determined to be healthy and acceptably vigorous for virus titration and
antiviral tests. Being seconds, hatchery personnel provided assurance that
these birds were not vaccinated with anti-A! vaccines currently in use. Poults
were brooded in electrical heated battery brooders at the Utah State
University (USU) Poultry Farm. The temperature was regulated at 32.20C for
the first 5 days and then reduced 3-5 degrees every other day, so on day 11
the poults were accustomed to approximately 23.aoc temperatures. Then
they were moved to isolation sheds on the USU Veterinary Science farm .
Birds were fed #1 Starter Mash £Q. !i.llli.l.un. obtained from Moroni Feed Co.
Terramycin (Oxytetracycline Hydrochloride)powder was mixed with the feed at
the rate of 500 grams per ton , in order to limit the severity of secondary
infections that often accompany AI infections. Water was provided S!Q !i.llli.lml.
~

Poults held at the USU Veterinary Science Farm were housed in 61 em
high plywood boxes measuring 76 cm2 with a chicken wire frame top, hinged
so that access to the birds was through the top of the box. The boxes were
bottomless and stood on the concrete floor. Approximately 3" of pine
shavings were spread on the floor as bedding . Bedding was changed weekly
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and all facilities were disinfected between groups of birds with sodium
hypochlorite (Ciorox ••) .
Quarantine Procedures
Personnel working with infected birds were subjected to stringent
hygiene and infection control procedures . Persons who had come in contact
with infected birds were not allowed access to the USU Poultry farm . All
deliveries of birds or feed were made to a clean drop point. Personnel
exposed to the Al-infected birds would then pick up delivires and deliver them
to the AI facility. Personnel coming in contact with infected birds were
required to wear surgical mask, gloves, disposable outer garment and rubber
boots that remained in the contaminated isolation shed at all times. Upon
leaving the contaminated shed , personnel were required to disinfect any
articles being removed as well as exposed surfaces and hands. These
precautions were necessary to avoid the possible spread of AI to uninfected
control birds housed in the USU Poultry Farm.
Induction of Virus Infection
Infection of poults were accomplished by passing an oral gavage
needle (1 0 ga.) through the larynx as it opened upon aspiration . Virus in a
volume of 0.1 ml thus was deposited in the bronchi. Virus used in antiviral
trials was A/Turkey/Sanpete/86 diluted to 1o3 .3 CCIDso/0.1 mi.
In indicated assays birds were infected via intranasal infection, by
holding the poult upside down and openinQ the beak, exposing the nasal
cleft. Virus inoculum in the amount of 0.1 ml was deposited in the sinus cavity
using an oral gavage needle (16 ga.).
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Drug Treatments
Four different antiviral drug trials were conducted, 2 using ribavirin and
2 using amantadine. Each of these drugs was administered via 2 different
aerosol systems. The first utilized a collision -type small-particle aerosol
generator (Figure 3) obtained from the U.S. Army, (Dugway Proving Grounds ,
Utah) facility. This device produced aerosol particles measuring
approximately 1-5 1-1m in diameter. The aerosol was delivered into a stainless
steel chamber where the birds were exposed for 3.8, 7.5, 15 and 30 minutes .
The second aerosol system was a Fogmaster POW-A-JET '" , Fogmaster
Corporation, (Deerfield Beach, Florida). This fogger delivered an aerosol with
particle sizes varying from 30 to 100 1-1m. into a lexan plastic chamber of
identical dimensions as the stainless steel chamber (54.5 em x 18.1 em x 22
em) used in previous experiments. The total dosage again was controlled by
varying the treatment time. The length of treatment was varied to administer
approximately the same volume of drug per treatment, whether by large- or
small -particle aerosol. The drug preparations consisted of 20 mg/ml in sterile
saline and approximately 52.5, 105, 210 and 420 mg were administered per
cage per treatment. Treatments began 18 hours post-virus exposure using
ribavirin and 24 hour previous to virus exposure when using amantadine.
Treatments were given twice daily for 3 days. On day 4, half of the infected
birds were sacrificed and lung tissues were collected and scored as
described under Infection Parameters .
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Fig. 3. Collision-type small-particle aerosol generator and chamber.
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Infection Parameters
Hea~h

Score. Daily health scores were collected as an average of the

birds in that cage, based on the presence of individual signs of disease, as
follows :
0:

Healthy, alert birds

1:

Coughing , sneezing or other respiratory distress

2:

Ruffled feathers . holding wings away from body

3:

Droopy head , sinus exudate or swelling

4:

Unwillingness to move, nesting down, stargazing

Birds were observed each day at the same time and individual bird
scores were used to calculate an average cage score.
Lung Score. On day 4 of each experiment one-half of the infected and
treated birds and 4 to 5 normal control birds were sacrificed and the lungs
removed . The lungs were scored on a 0-4 scale based on the visual
determination of percent of total area of the lungs that appeared consolidated
(consolidation being defined as a reddening or darkening deviation from the
normal salmon pink color of lung tissue , and firmness or loss of the spongy
response to touch} as follows :
0:

No consolidation

1:

25% consolidation

2:

50% consolidation

3:

75% consolidation

4:

100% consolidation

Water Consumption. Each morning the waterers were filled from a 1000
ml graduated cylinder and the volume of water required was recorded . A
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decrease in water consumption has been reported to coincide with the
development of influenza infection in mice (McGahen and Hoffmann 1968) .
Recoverable Virus Titer. The tissue samples collected for lung scores
were frozen at -8ooc and later thawed and homogenized in either an OmniMixer homogenizer (Newton, Connecticut) or a Stomacher (Unique Scientific
Apparatus, Cincinnati, Ohio) . Tissues from the ribavirin-aerosol experiment
were 15% weight/Volume (w/v) homogenates; all other homogenates were
20% w/v, to conserve on homogenizing media and increase the possibility of
virus isolation. Homogenizing medium was MEM (minimum essential
medium) with 0.5% NaHC03, 1% sorbitol (Gibco Laboratories Ufe
Technologies, Grand Island , New York) . Tissues were homogenized for 1
minute, decanted to 5 ml snap cap vials and refrozen at -8ooc. Samples later
were thawed, diluted in serial 10-fold dilutions (diluted in MEM o.1 %NaHC0 3 ,
1% sorbitol, 50

~g

gentamicin/mi. without serum), and plated on 96-well

microliter plates (Titertek, Hayward , California), which had been seeded 24
hours previously with single passed CEF cells.
Weight Gain. Poults were weighed prior to infection and treatment and
prior to sacrifice and tissue collection on day 4 post-virus exposure . Average
weight gain or loss was used to indicate severity of infection and toxicity of
drug treatments.
HA Titration. The same tissues used for recovered virus titer were used
to do HA titrations using 0.3% suspensions of chick red blood cells (red blood
cells provided by the USU Poultry Farm) . A 0.1 ml of each sample was serially
diluted 1:2 through 1:128 in phosphate-buffered saline (PBS). Bed blood cell
suspension then was added and mixed via repeated pipetting. The tests then
were allowed to stand and readings were taken at 30 minutes and 2 hours. A
solid button of sedimented red blood cells was read as a negative test. Any
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disruption of the button formation was read as a positive test. The red blood
cells were suspended in chilled (PBS).
Cell Culture . Primary CEF, MOCK and Wl -38 (Human Embryonic Lung)
cells were maintained in MEM with 5% fetal bovine serum (FBS) and 0.1 %
NaHC03 without added antibiotics, or Basil Minimal Eagles (BME) with 10%
FBS, 0.1% NaHC03 (Gibco Laboratories Life Technologies, Grand Island,
New York), in a 3rC incubator with 5% C0 2. The CEF cells were primary
cultures generated by the trypsinization of decapitated 10-day-old ch ick
embryos . Cells were grown for 3 to 4 days in Corning tissue culture flasks
(Palo Alto, California). For cell culture titrations and antiviral tests, 96-well
microliter plates were seeded at 3.5 x 1Q5 cell/ml with 0.2 mi/Well. Virus
dilutions and maintenance media for virus and trypsin titrations used
appropriate cell culture media devoid of serum.
In Vitro Antiviral

In vitro antiviral tests were conducted utilizing the

Sidwell and Huffman micro tissue culture antiviral test system (Sidwell and
Huffman 1971) . The 96-well flat -bottom plates were prepared with 24-hourold confluent monolayers of single-passed primary CEF cells.
Drugs were diluted in MEM contain ing 0.18% NaHC03 and 50 flg
gentamicin/ml but devoid of serum . Drug dilutions were made utilizing half-log
dilutions starting at 1000 flg/ml through 1.0.f.lg/ml.
The growth media was splashed from the plate and 0.1 ml of each drug
dilution was placed in each of 4 replicate wells, with dilution media placed on
the virus controls. A 0.1 ml sample of the appropriate virus dilu1ion then was
added to each of 3 of the test wells and the virus controls; the fourth well
received virus dilution media in order to serve as a toxicity control. The plates
were checked 3 and 5 days later for adequate CPE development, and were
read on day 5. Virus control and test well CPE were graded on percent basis
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as described earlier. From this data virus rating (VA) (percent CPE of virus
control - percent CPE of test/ 10 X number of test wells) , effective dose 50%
end point (E0 50 ) (obtained by plotting percent inhibition vs. drug dilution and
estimating the 50% dose from line intersection), Cytotoxic dose 50% end point
(CD 50 ) (visual determination of 50% toxicity in toxicity control wells) and
therapeutic index (TI) {the ratio of CD 5 ofED 50 ) were determined .
Titrations . Turkey lung and egg preparation samples were titered in 96well microliter plates seeded as above. Triplicate wells were inoculated with
serial 10-fold dilutions . End points were determined via microscopic
examination for visually recognizable CPE, and in some cases the CPE was
verified by collecting supernatant from the last positive wells in the titration
following a freeze-thaw process . These supernatants then were diluted for HA
titration and positive HA used to indicate correct reading of visually
recognizable CPE.
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RESULTS
Development of a Cell Culture and Assay
System for Avian Influenza Virus.
To establish cell line infectivity of these AI viruses, several experiments
were conducted to establish which cell line or lines would be most susceptible
to virus induction of CPE.
Since trypsin ization of the viral HA has been shown to increase the
infectivity of certain influenza viruses , the viruses available to us were
therefore titrated in various cell lines at trypsin concentrations varying from 0 to
40

~-tg/m l

(Table 3).

Both viruses isolated from Utah poults exhibited production of CPE in
primary CEF cells without addition of trypsin ; however, virus titers of the 1986
isolate increased with use of trypsin at 20

~-tg/ml.

The 1985 isolate virus titer

decreased by 0.5 log 10 using moderate trypsin concentration . The only other
virus showing a response to the trypsinization in CEF cells was the
A/Turkey/Mass/65 isolate which had higher infectivity (0.2 log1ol. at the 40
~-tg/m l level of trypsin. None of the titer differences were significant statistically.

The A/Turkey/Mass/65 (H6N8) pool produced in eggs, reproduced
modestly well in MOCK cells (1 04.4 CCID 5 of0.1 ml) as determined by visual
CPE detection , but did not produce readable CPE in MDBK cells beyond a
1o-1 dilution. In 10-day-old embryonated chicken eggs , the virus titer was
107.6 and the HA titer was 102.7 (last dilution showing positive HA) . Of
·particular interest, because of direct applicability to Utah agriculture, were the
2 viruses isolated in Sanpete County, Utah. The earlier isolate
(A/Turkey/Sanpete/85 [H6N8]) had lower titers when grown in embryonated
eggs as titered in CEF than the later viral isolate (A/Turkey/Sanpete/86

Table 3.--Effect of Trypsin Treatmenta on In Vitro Virus Infectivity
Virus Titer (log 1o CCIOso)b
Cell line:

MOCK

MOBK

MOCK

Primary CEF

Primary CEF

Primary CEF

Virus:

Nfur/Mass

NTur/Mass

High Passage
Nfur/Mass

NTur/San/85

NTur/San/86

NTur/San/86
1 Turkey Passage

Trypsin Cone .
ug/ml
0

2.5

0

1.5

4.0

5.:>

0

1.5

2

2.5

1.5

N~

NT

NT

10

2.5

1.3

1.5

NT

NT

NT

20

2 .5

1.3

1.5

3.5

6 .5d

1.7

30

2 .5

1.5

1.5

NT

NT

NT

40

2.7

1.5

1.5

NT

NT

NT

~rypsin

in the concentrations indicated was included in virus medium and subsequently added to the various
cells and incubated with virus and cell until viral CPE was determined.
been cuHure infectious dose 50% end point.
CNT = Not titered.
deacterial contamination found in this trtration; therefore, the validrty of this higher titer is questionable.

1\J

co
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[H1 ON9]) . The titers were 1Q4 .0 and 1QS .3 , respectively in these cells. None of
the AI viruses grew to appreciable titers in MA 104 or L cells. Although they did
reproduce slightly better in Wl -38 cells, the titers still were too low to be useful.
Although the titer was slightly lower, more consistent CPE from the
A!Turkey/Sanpete/85 (H6N8) virus was found in CEF cells. Antiviral tests
using this system appeared more reliable than tests utilizing the later Utah
isolate A!Turkey/Sanpete/86 (H1 ON9) due to inconsistency of infection in the
virus controls.
Antiviral drug tests in vitro utilizing a. one-half-Jog dilution scheme from
1000 f.Lg/ml drug concentration to 1.0 mg/ml demonstrated good antiviral
activity for both ribavirin and amantadine (Table 4) .
Ribavirin was strongly active down to the 100 f.Lg/ml treatment level with
no cytotoxicity seen at the levels used in this test. The 50% effective dose
(EDsol. determined by plating dose to percent inhibition, was 66 f.Lg/ml.
Amantadine tested in vitro exhibited 75-1 00% toxicity at 1000 and 320
f.lg/ml ; antiviral activity was seen at all lower dosages employed. The EDso
was determined to be approximately 8.3 f.Lg/ml.
The percent toxicity and inhibition of AI in cell culture are summarized in
Table 5.
Development of an In Vivo
Avian Influenza Test System
Inherent in the development of an in vivo system for AI was the
verification of an applicable infection procedure. In such procedures the gross
qualification of illness should be demonstrated in addition to the
microbiological quantification of the severity of the illness.
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Table 4.--lnhibition of Avian Influenza (A/Turkey/Sanpete/85 [H6N8)) Virus
Infection in Primary CEF Cells by Aibavirin and Amantadine
Concentration
b!9Lm1

Percenta
To xicit~

Ribavirin
Avg. Percentb
QPE lnhibi!iQn

Amaot2d i n~

TQ~S i c i ~

Avg.
QEE

Percentb
lobibiliQn

Percenta

1000

0

0

100

100

Toxic

Toxic

320

0

12.5

83

100

Toxic

Toxic

100

72

75

25

67
67

0

21

32

0

75

0

50

25

10

0

87.5

0

25

38

49

3.2

0

96

0

0

38

49

1.0

0

100

0

0

58

23

7
7
apercent toxicity is a visual determination based on a single microtiter 96 -well
sample at each concentration .
bPercent inhibition = virus control CPE - test CPE I virus control CPE.

Table 5.--Summary of the Inhibition of Avian Influenza A (A/Turkey/Sanpete/85
[H6N8)) Virus Infection in Primary CEF Cells by
Ribavirin and Amantadine
Ri!;lavirin
CD soa

1000

ED sob

66

~g/ml

~g/ml

Amantadine
32 ~g/ml
8 . 3~g/ml

VAC

>0.8

0.5

Tid

>15.2

<3 .9

aso% Cytotoxic dose
b50% Effective inhibitory dose
cv irus Rating
dTherapeutic index
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Infection with A!Iurkey/Mass/65 . Virus (A!Iurkey/Mass/65) grown in
eggs, when administered via the intranasal route, was found to establish a
mild sinusitis in 21-day-old turkey poults. No deaths were observed. One bird
infected with undilute virus developed a severe sinusitis on day 7 of infection,
with sinus exudate, star-gazing {head tipped as though looking at the stars)
and loss of equilibrium exhibited. Several birds developed swelling around
the eyes. On day 4, however, following the initial development of signs, all
clinical evidence of disease had abated . The disease signs were erratic and
inconsistent, with no apparent infection dose response . Birds in all levels of
infection (undilute through 10-4, or 104 .4, 103.4, 102.4, 101 .4 CCIDso/0.1 ml)
showed mild to no signs of clinical illness.
Infection with A!Iurkey/Sanpete/86 . In vivo titration of
A!Iurkey/Sanpete/86 in birds infected via laryngeal gavage also resulted in no
deaths and only mild disease signs, with 62% of birds exhibiting indications of
respiratory distress and sneezing . Lungs from these distressed birds showed
highest consolidation at the 1o-1.0 level of virus inoculum , which represents
1o3.8 CCIDso /bird. See Table 6 for virus inoculum, and resulting lung scores.
Infection with Turkey-passed A!Iurkey/Sanpete/86 . Lung homogenates
collected on day 4 of infection from 10-day-old turkey poults infected with
A!Iurkey/Sanpete/86 was titrated in birds. Jhis pool also produced no deaths,
and only 2 birds of 51 showed any signs of disease. More profound in this
case was an apparent infection dose-response in feed consumption . Although
these differences in food consumption were not quantified, all feeders were
filled to the same level and the relative volumes were recorded after 24 hours.
This was done only once, at the peak of infection. Birds infected with virus
diluted to 1Q·4 consumed approximately 90% ; those at 1Q·3 consumed 100% ,
those at 10-2 consumed 75%; those at 10-1 consumed 60%, and birds infected
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with undilute virus consumed 50% of the feed given. On day 5, one-half of
these birds were sacrificed and the lungs scored. The lung scores
demonstrated no significant differences between uninfected controls and all
levels of infected birds. See Table 6.

Table 6.--Average Lung Scorea of Turkey Poults Infected with Avian
Influenza
Virus Dilutionb
Virus
Strain

Normal
Control

100

1Q-1

1Q-2

1Q-3

A/Turkey/San/86

1.9

1.8

2.9*

1.7

1.8

A/Turkey/Mass/65

1.8

1.1

1.6

1.4

2.0

A/Turkey/San/86/ 1tc

2.8

3.4

3.4

3.0

2.9

BLungs collected on day 4 of infection and scored from 0 (no consolidation) to
4 (1 00% consolidation) .
bTiter of virus strain used (CCI0 50 ): A/Turkey/Sanpete/86 = 1Q4.8;
A/Turkey/Mass/65 = 1Q4.4; A/Turkey/Sanpete/86/ 1! = not determined.
CVirus passed one time through turkey poults.
*P<0.05
Due to the relatively high lung scores in uninfected controls, other
possible causes of consolidation were considered. A bacterial isolate was
found in all lung samples tested. This will be discussed later.
Virus recovery from infected birds in these titrations was sporadic at the
.various levels of infection . Positive isolations were found as determined by
viability in 10-day-old embryonated hens' eggs. Although these results
seemed erratic, there was an apparent infection response curve (Table 7) .
One embryo death did occur in the uninfected controls; this is presumed to be
due to technique, although this death occurred on day 5.
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Table 7.--Egg Infectivity of Homogenates of Turkey Lungs Infected with
Avian Influenza (NTurkey/Sanpete/86) 3
Lung Homogenate
Dil ution

ird
2

3

4

10-1

2/10

4/10

3/10

1/10

1Q-2

1/10

0/ 10

0/10

0/10

10-3

1/10

0/10

0/ 10

0/10

Uninfected lung

0/10

Diluent control

1/6

arotal embryo deaths 1/total embryos infected with lung homogenates.

In Vivo Drug Tests
Treatment of young turkey poults with a small-particle aerosol of
ribavirin beginning 18 hours post-virus exposure (Table 8) showed a
significant increase in water consumption at treatment durations of 30, 15, and
7.5 minutes. Increases in water consumption ranged from 10 to 14 grams
above the control and lowest treatment group. Weight gain, however, was
highest in the 7.5 minute treatment. This was the only significant weight gain
in this trial. Lung HA titer also was significantly reduced at the 30-minute
treatment group, showing a log2 titer of 1, while virus controls demonstrated a
titer of 2.6. There also appeared to be tendency toward reduced lung score ,
although this parameter did not show significance at any treatment duration.
Similar treatment of infected poults with a large-particle aerosol or fog of
ribavirin with treatments beginning 24 hours post-virus exposure did not cause
significant differences between the 4 treatment groups and the untreated

Table 8.--Effect of Treatment of Avian Influenza Virus-Infected Turkey Poults with Small-Particle Aerosols of Ribavirina
Treatment
Duration
(min/
treatment)

Total
Ribavirin/
Cage
(mg)

Toxicitv C<rtrol
Mean
Mean H20
Wt.
ConsumptionC
Gainb (g)
(mVbird)

Mean
WI .
Gainb ,h (g)

Infected Treated
Mean
Mean H20
ConsumptionC
Lung
Scored
(mVbird)

Mean
Lung HA
Titer" (Log2}

30

420

125" 27.3

108" 5.15

140

104*" 7.1

2.7" 0.5

1.0.. " 0.6

15

210

124" 23.2

112 " 10.6

117

103*" 8.2

2.0" 0.3

4.0" 0.7

7.5

105

125" 27.3

126" 12.4

145*

108* " 14.3

2.1 " 0.3

2.0 " 0.7

3 .8

53

126 " 16.2

11 2" 15.7

129

83" 6.4

1.7f " 0.4

3.0 " 1.5

Normal Control

0

g

1.5" 0.6

0.2" 0.2

2.9" 0.2

2.6" 0.6

g

Virus Control

g4" 8.7

3Treatment bid x 3 beginning 18 hr post-virus exposure; aerosol generated by a collison -type aerosol device.
bDifference between weights determined on Day 0 and Day 5.
CDetermined on Days 1 through 6.
dscores assigned from 0 (normal) to 4 (maximal) on lungs taken 4 days post-virus exposure.
eviral HA determined on lungs taken 4 days post-virus exposure.
fonly 3 lungs scored at this treatment level compared to 5 in other groups.
gNormal control housed at separate facility ; weight gain and water consumption data were therefore not gathered.
hstandard deviation of these data cannot be calculated due to unpaired nature of the data.
*P<O.OS
••P<0.01
(Treatment groups n ; 10 except 3.8 min. where n ; 7. Control groups n ; 5 except 3.8 min where n ; 3.)

(..)

01
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controls (Table 9) . Mean weight gains remained constant except for birds in
the shortest treatment duration group, where there appeared to be an
appreciable increase in weight. This increase was not significant, due to a
small sample size in the final weight average. Water consumption, mean lung
score and lung HA titer showed very little or no variation .
Birds treated 24 hours pre-virus exposure with a small-particle aerosol
of amantadine (Table 10) showed consistent water consumption , only varying
from 91 to 101 ml/bird . Mean lung HA titers appeared to show a mild dose
response curve with a mean titer of 2.1 (Log 2) at the 30-minute treatment
duration and a titer of 3.3 at the 7.5-minute treatment duration. The 30-minute
treatment group exhibited significant reductions in the mean lung score with
an average score of 0.78, or approxi mately a 20% consolidation, while the
infected untreated controls averaged approximately 33% consolidation. The
use of a fog of amantadine to treat poults infected with AI beginning 24 hours
prior to infection (Table 11) resulted in a uniform weight gain in all groups
except the 1.5 second treatment, in which a significantly lower weight gain
resulted . All the other treated and infected groups' weight gains were
consistently lower than the virus controls by 6-7 gm. Ukewise, the highest
water consumption was in the virus controls; the lowest water consumption
occurred in the 3-second treatment group with essentially a dose response
seen . Mean lung HA titers also varied in an approximate dose response
fashion , with the 2 significantly low titers seen in the 2 groups receiving the
longest treatments. The highest HA titer was not in the virus control but in the
shortest treatment group. Mean lung scores in th is trial did not vary
significantly in any of the treatment groups, with all the scores ranging
between 2 and 2.5.

Table 9.--Effect of Treatment of Avian Influenza Virus-Infected Turkey Poults with a Fog of Ribavirina

Treatment
Duration
(sec/
treatment)

Total
Ribavirin/
Cage
(mg)

Toxicl!y Control
Mean
Mean H20
ConsumptionC
Wt.
Gainb (g)
(mVbird)

Mean
WI .
Gainb,g (g)

Infected Treated
Mean
Mean
Mean H20
ConsumptionC
Lung
Lung HA
Scored Titere (Log2)
(mVbird)

3.0

420

91

±

14.3

98

±

10.6

84

104

8.5

1.3

±

0.5

2.6

±

0.5

1.5

210

85

±

15.8

96

±

8.8

81

94

±

8.3

2.0

±

0.4

3.2

±

1.4

0 .75

105

80

±

9.2

80

±

9.0

82

94

±

8.3

1.1

±

0.3

2.8 ± 1.1

82

±

7.2

89

±

18

117

98

±

7.3

0 .38

52 .5

Normal Control

0

Virus Control

0

86

95

±

+

4.7

1:4

±

0.3

3.0

±

0.6

0.7

±

0.2

3.0

±

0

1.7

±

3.4

2.0

±

0.9

arreatment bid x 3 beginning 18 hr post-virus exposure; fog generated by a Fogmaster 6309 Power-jet fogging device.
bDifference between weights determined on Day 0 and Day 5.
CDetermined on Days 1 through 6.
dscores assigned from 0 (normal) to 4 (maximal) on lungs taken 4 days post-virus exposure.
eviral HA determined on lungs taken 4 days post-virus exposure.
'Normal controls housed at separate facility; weight gain and water consumption data were therefore not gathered.
gstandard deviation of these data cannot be calculated due to unpaired nature of the data.
(Note: no statistical significance using any parameter. Treatment groups n
where n = 6.)

= 10.

Control groups n

=7 except 0.38 sec.

Table 10.--Effect of Treatment of Avian Influenza Virus-Infected Turkey Poults with Small-Particle Aerosols of
Amantadinea
Treatment
Duration
(min/
treatment)

Total
Amantadine/
Cage
(mg)

Tol!iciiJI Qontrol
Mean
Mean H20
ConsumptionC
WI.
Gainb (g)
(mVbird)

Mean
WI .
Gainb (g)

lnfecl!;!d Treated
Mean H20
Mean
Consumptionc
Lung
Scored
(mVbird)

30

420

108

±

8.0

ndf

15

210

56± 16.3

115

±

11 .5

nd

7 .5

105

60 ± 20.0

111 ± 9.9

nd

92

±

3.8

53

65 ± 5.2

118

nd

97

±

61 ± 9.7

105 ± 10.5

Normal Control

106 ± 6.5

±

8.1

Virus Control

nd

Mean
Lung HA
Titere (Log2)

0.8* ± 0.3

2.1 ± .8

1.3

0.8

2.9 ± .5

12.2

0.9 ± 0.3

3.3 ± .8

8.0

1.4

±

0.3

1.5

±

0.3

91 ± 10.0
100 ± 7.5

108 ± 7.3

±

1.4 ± 0.4

4.0

±

0

2.6 ± .8

~reatment bid x 3 beginning 24 hr pre-virus exposure; aerosol generated by a collison-type aerosol device.

bDifference between weights determined on Day 0 and Day 5.
Coetermined on Days 1 through 6.
dscores assigned from 0 (normal) to 4 (maximal) on lungs taken 4 days post-virus exposure.
eviral HA determined on lungs taken 4 days post-virus exposure.
fNo1 determined.
*P<0 .05
(Treatment groups n

= 15 except 3.8 min. where n = 14.

Control groups n

=6 except 30 min. where n =5.)
w

())

Table 11 .--Effect of Treatment of Avian Influenza Virus-Infected Turkey Poults with a Fog of Amantadinea

Treatment
Duration
(sec/
treatment)

Total
Amantadine/
Cage
(mg)

Toxici!y Control
Mean
Mean H20
Weight
ConsumptionC
Gainb,f (g)
(ml/bird)

Mean
Weight
Gainb,f (g)

Infected Treated
Mean H20
Mean
ConsumptionC
Lung
Scored
(ml/bird)

420

85

125 ± 15

69

1.5

210

69

127 ± 5

48

130

0.75

105

92

69

135

0.38

53

88

Normal Control

0

105

Virus Control

162

±

12

162 ± 9
172

±

68

2.1 ± 0.4

2 .7'

8

2.5

±

0.3

2 .1' ± 0.6

12

2.1

±

0.4

4.0

±

0.5

7

2.0 ± 0.5

5.1

±

0.2

1.3

±

0.1

4.3

±

0.4

120' ± 12

3.0

134

±

±
±

Mean
Lung HA
Titere (Log2l

24

0

75

153

±

15

2.1

±

0.3

arreatment bid x 3 begining 24 hr pre-virus exposure; fog generated by a Fogmaster 6309 Power-jet togging device.
bDifference between weights determined on Day 0 and Day 5.
CDetermined on Days 1 through 6.
dscores assigned from 0 (normal) to 4 (maximal) on lungs tak£1n 4 days post-virus exposure.
eviral HA determined on lungs taken 4 days post-virus exposure.

I standard deviation of these data cannot be calculated due to unpaired nature of the data.
'P<0 .05
(Treatment groups n

=15.

Control group 3.0 sec. n

=8, 1.5 sec. and normal n = 7, 0.7 sec. and 0.38 sec. were

n

=6.)

±

0.5
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Graphs of the per-day water consumption averages, per-treatment
group, of birds treated with small-particle aerosol of ribavirin , yielded erratic
results . The virus controls and the normal controls demonstrated the most
linear results (Figures 4 and 5) . It is of interest to note that all the treatment
groups showed .a downward spike at days 3 and 4. All groups, other than the
3.3-minute treatment and the normal controls , exhibited a general upward
trend.
Similar data from trials where poults were treated with ribavirin fog
demonstrated a more consistent upward tendency, with normal control and the
3-second treatment groups having the highest water consumption at day 7.
The water consumption of all treatment groups remained fairly closely
bunched until day 6, when they experienced a seemingly random divergence
(Figures 6 and 7).
The graph of water consumption of poults treated with small-particle
aerosols of amantadine (Figures 8 and 9) indicated wide rises and falls from
day to day. From day 1 to day 2 a sharp, increase occurred , with an adjacent
sharp valley at day 3; the least affected of the treatment groups at day 3 was
the 15-minute treatment, wherein occurred the most stable increase over the 7
days . From day 3, all groups had a sharp increase in water consumption to
day 5 or day 6, where they again exhibited declines to levels nearly equal to
those seen at day 1 (Figures 10 and 11 ) .
Water consumption data for poults treated with amantadine via fog
demonstrated the most consistent linear results (Figures 10 and 11). Normal
controls showed the highest water consumption overall with the only deviation
being on day 4. In all treatment groups, water consumption remained closely
grouped and linear through the 9 days of data collection, while both virus and
normal controls both exhibited generally higher water consumption.
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DISCUSSION
In Vitro Infectivity Potentiation
Passage of A/Turkey/Mass/65 in MOCK and MDBK cells resulted in a
low and constant virus titer throughout, suggesting that the trypsinization of the
virus did not potentiate its infectivity. This may be due to varying host
passages, where a virus isolated from turkeys was passed in hens' eggs and
then titered in the above cell lines resulting in a possible attenuation of cell line
infectivity.
Another possible cause for the low titers may have been the improper
exposure of the F protein at HA cleavage by the trypsin . This F protein is the
active binding site after HA cleavage (Murphy and Webster 1985) .
A most plausible reason , however, is the fact that these virus pools were
produced in hens' eggs, and consisted of pools of collected allantoic fluids. It
is possible that the natural trypsin inhibitors ovomucoid and ovoinhibitor, found
in hens eggs, inhibited the trypsin cleavage of the viral HA (Kassell 1970).
Appleyard and Maber (197 4) demonstrated that the presence of soybean
trypsin inhibitor at the 0.5 mg/ml level greatly reduced the plaque-enhancing
action of trypsin . This could create the condition seen in Table 3, where virus
titers are constant throughout. The one exception in the trypsin experiment
was the MOCK titration of A/Turkey/Mass in the presence of 40 ug/ml trypsin .
At this point the virus titer jumped from 2.5 to 3.4, suggesting the possibility that
the trypsin had overwhelmed the inhibitors and potentiated virus infection .
In Vitro Antiviral Studies
The antiviral activity of ribavirin and amantadine against AI was readily
seen in vitro. Ribavirin 's VA of >0.8 and Tl of > 11 .6 were consistent with the
strong inhibition of other strains of influenza reported by other researchers
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(Huffman et al. 1973, Sidwell et al. 1972). The VA is greater than 0.8 due to
the absence of toxicity in this test with ribavirin , which has been reported to
demonstrate some toxicity at or above 320 f!g/ml (Huffman et al. 1973; Sidwell
et al. 1977).
The strong in vitro antiviral activity of amantadine against the AI viruses
used in these studies (VA of 0.5 and Tl >1 .5) confirmed similar activity against
other influenza viruses reported by Hoffmann (1973) .
These in vitro studies run prior to the experiments in turkey poults
indicated that the virus used in infecting the turkeys was indeed sensitive to the
effects of both drugs.
Both amantadine and ribavirin would have had higher VA 's if the virus
had shown a greater CPE in the virus controls, making the test more definitive.
The low VR 's may have been due to the low virulent nature of the Utah virus
isolates , and the possibly the low number of passages in cell culture achieved
with these isolates.
In Vivo Infectivity Studjes
The difficulty in obtaining definitive results in the antiviral portion of the
project lies, in part, in the difficulty of producing quantifiable signs of illness
with the viruses available to us. Demonstrable signs of illness were not seen
using the first virus (A/Turkey/Mass/65) studied , other than mild sinusitis in 2 of
51 birds . This level of infection was considered unacceptable for use in
antiviral studies. Attention then was turned to one of the fowl plague viruses,
but this concept of using such a virulent agent was negated by the Utah State
Veterinarian, because the risk of accidental release of a highly pathogenic
organism was too great. Thus , the importation of a virus that would provide
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highly quantifiable clinical signs in turkey poults could not be considered
additionally.
Interest then was turned to 2 viruses isolated in turkey poults in Utah by
Brigham Young University researchers . These viruses were reported to have
caused in Utah turkey flocks mortality losses of 3-5% (Ahmed and Jensen
1987) . Where E. coli infections complicated the virus disease, losses in flocks
were reported as high as 20 -30% (Ahmed and Jensen 1987) . This Utahisolated virus was then the best option for a strain that would be acceptable for
use in the state.
These viruses offered , at best, mild signs of illness. This may have been
at least in part due to the fact that the virus had been passed in hens' eggs at
Brigham Young Univers ity and again at USU. This non-original host passage
may have attenuated the virus for turkey poults. This idea is supported by data
in Table 6, where lung scores are consistently higher in birds infected with
virus passed once in turkey poults after the hens' egg passages. The
difference , however, is minimized by the high lung score found in the normal
controls.
This difficulty in producing quantifiable signs or lesions in
experimentally infected birds has plagued other researchers as well (Beard
1984, Otsuki et al. 1981) . This problem of low disease signs induced by AI ,
seems to be characteristic of the non-highly pathogenic strains of AI.
Karunakaran (1984) found that of infected untreated birds, only 33% had
recoverable virus in the lungs.
The unsuccessful efforts to assay recoverable virus left us unable to
obtain consistent results. Turkey lung homogenates assayed in human
embryonic lung cells (WI 38) showed no CPE at all , even in virus controls.
Titrations utilizing primary CEF cells yielded erratic results . All samples were
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titered on 2 separate occasions; in the first titration all samples (1 04 of 11 0)
yielded positive CPE, including all the normal controls. The same pattern of
low titers throughout the experiment, with occasional peaks in particular
samples (except for normal controls) also has been reported by Karunakaran
{1984) where 50% of all samples showed titers below 10 1 .
Two weeks later, samples were rethawed and again titered . On this
occasion 45 of 11 0 yielded positive CPE, and positives again were seen in
the normal controls. If these titers actually were due to recovered virus, this
reduction in titer levels easily would be explained by the freeze/thaw action on
the virus. This left HA as the only reasonable quantifying measure of infection
in this system. It is important to note the presence of positive HA in 3 out of 3
of the normal controls from the amantadine; fog experiment. This was of
particular concern because positives were found throughout all 3 of the
titration systems described above, indicating the possibility of cross
contam ination between infected birds and uninfected controls. Although
every reasonable effort to eliminate this possibility was taken , it appears that it
may have occurred.
In an effort to eliminate possible causes of these positive results, HI tests
using antibody to Newcastle disease virus (Cy1immune. lot 84007, Lee
Biomedical Research, San Diego, Ca.) did not demonstrate inhibition of HA in
these samples. With the consistent nature of the HA in these samples
(consistent in that it was still seen through 6 repeated freeze/thaw cycles) and
their effect on the results of the 2 antiviral studies, concern remains as to what
is the cause of this red blood cell reastion.
With this concern in mind, HA positive samples from the various normal
controls were sent to the National Veterinary Services Laboratories (NVSL)
with the approval of Dr. Stan Flora, Utah State Veterinarian . Dr. Dennis Senne
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of the NVSL reported that, using primary embryonic kidney cells and
embryonating chicken eggs , no evidence of viral infection was detected. HA
tests on amnionic and allantoic fluids from embryos, where death was induced
by these samples, were negative. It was thus determined by the NVSL that
non-specific hemagglutination was occurring.
The use of health scores was found to be unproductive in this system
due to the difficulty in visualizing signs of AI. The appearance of signs on
different days post infection for different birds in a given treatment group
diminished the usefulness of the average health score for the cage. This is
due to the rapid appearance and abatement of what few signs were visible,
leaving very few, if any, birds demonstrating signs concomitantly. Thus the
health scores viewed were very low and demonstrated no significance.
In Vivo Antiviral Studies
Ribavirin treatment via small-particle aerosol caused significant
reductions in lung HA titer and increases in water consumption, indicating
reductions in the severity of the disease. This animal model system, utilizing
strains of AI with low pathogenicity may not. predict fairly the effectiveness of
ribavirin 's ability to prevent death of turkey poults, which would be likely with
viruses of greater virulence. However, the data do suggest potential efficacy.
Positive results from ribavirin treatment of AI infection in chickens was
demonstrated by Karunakaran (1984), although it was a mild response
. (approximately 15% reduction of recoverable virus) and treatment was via oral
gavage.
The lack of significant reduction of any disease parameter in the
ribavirin fog experiments indicates that treatment via large-particle aerosols
are ineffective in prevention of treatment of AI in turkey poults. Presumably this
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is due to the particle size of the aerosol, because other researchers have
shown significant reduction in lung lesions, recoverable virus titers and
significant increase in survival rate when using ribavirin in small-particle
aerosols (Arensman , Dominik and Hilmas 1977) . The function of particle size
in efficacious treatment is dependent on the depth of the penetration of the
drug-laden droplets into the respiratory tract. Large particles impinge on
surfaces on the mucous membranes, nares and bronchi, while the smaller
particles continue further into the interstitial spaces of the lung (Larson, Young
and Walker 1976; Spendlove and Fannin 1979), where greater surface area
facilitates more drug adsorption. However, there still remains the question of
whether this occurs in the airsac or lungs of avian species.
Both the small-particle aerosol and the fog treatments utilizing
amantadine produced significant reductions in the measured parameters.
After considering the results of the small-particle aerosol results of the
ribavirin experiments , it is surprising that the small-particle aerosol of
amantadine only showed significant reduction of mean lung score. Aerosol
(particle size is not known) work done by Karunakaran (1984) with
amantadine utilizing 4-week-old birds (vs. 10-12 day old poults used in these
experiments) , showed 20% reduction of positives detected. Positive
prophylactic effects of oral treatment with amantadine has also been
demonstrated by Lang, Narayan and Rouse (1970). Because of the relative
ease and availability of fog administration systems, the appearance of
reduction in mean lung HA, although not significant, does suggests the need
of further studies on this treatment system with amantadine.
The fog-administered treatment with amantadine indicated some
promise, in that mean lung HA was significantly reduced in what appeared to
be a dose-response fashion, although only the 2 longest treatment durations,
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reflecting maximum amounts of amantadine therapy, caused significant
reductions. This is consistent with the findings of other researchers using
amantadine via oral gavage (Lang, Narayan and Rouse 1970), aerosol
(Karunakaran 1984} and drinking water (Karunakaran 1984, Webster et al.
1985).
Water consumption data suggest a general decline in average
consumption on day 3 post-virus exposure. This is similar to findings of
McGahen and Hoffmann (1968). where at 36 hours post-infection they
reported a reduction in water intake in mice. These researchers also found
that the time after virus exposure when the reduced water intake occurred ,
varied with different virus strains, and used this to indicate the time to initiate
treatment. Such data also suggests that treatment via drinking water likely
would not be as effective as other treatment routes due to the fact that at the
peak of infection the poults would be

recei~ing

less drug. However.

Karunakaran (1984) found amantadine toxicity-induced death in drinking
water treatments, suggesting adequate treatment levels may be reached.
Three of the 4 drug trials were conducted during the July and August
months, raising the question of outside temperature effect on water
consumption . However, the correlation coefficients between water
consumption and daily high temperature suggest a minor effect of outside
temperature on water consumption .
The results of these experiments suggest the possibility of successfully
implementing a treatment program in the effort to control future outbreaks of
AI. This statement is cautiously made, however, because of some important
questions that remain unanswered. For example, the response of avian
species infected with highly virulent strains of AI to treatment with ribavirin has
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yet to be determined. Trials utilizing amantadine in this application were
performed by Lang , Narayan and Rouse (1970).
Stronger demonstration of CPE and clinical signs would greatly improve
the chances of making significant statistical decisions. Consistent recovery of
virus would greatly enhance this system , and it seems appropriate to test for
recoverable virus from multiple locations. Finally, better quantification of
aerosol dosages would be required , perhaps even the detection of blood
levels of the compounds used.
Overall, these experiments indicate the potential value of using
aerosolized administrations of anti-influenza drugs for treating AI infections in
domestic fowl. The method provides a means of dosing such birds to an
approximately equal extent; of specifically targeting infected respiratory
tissues, and of treating large numbers of birds the same time. When one
considers the intensification procedures currently in use in poultry production,
where literally thousands of birds may be in the same location, the applicability
of such aerosolization techniques for controlling potentially devastating poultry
losses due to AI appears quite obvious .
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CONCLUSIONS
Avian Influenza is an economically important pathogen with losses in
the last decade at approximately $100 million which justify looking for
alternative control measures. The control of avian influenza is in its infancy,
quarantine and depopulation yield questionable results, and better control
measures seem necessary.
This turkey poult model using gross signs, lung HA and recoverable
virus titers could be developed further for evaluation of antiviral agents in avian
species . Use of health scores, however, was impractical due to their low and
variable nature.
In this work, treatment of Al-infected poults with both small- and largeparticle aerosols of amantadine and ribavirin suggested possible efficacy in
the treatment of avian influenza in turkeys. However, the data derived in these
experiments were not conclusive, and further investigation is warranted.
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